EUVIMEDEUVIMED entdecken
Open Access

Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL

William E Rosa iD, Stephanie Napolitano, Natalie McAndrew, Betsy Jenkins, Wendy G Lichtenthal, Allison J Applebaum, William Breitbart, Manish Agrawal

Psychedelic Medicine · 01.06.2026 · 4 (2) · 97-106

DOI: 10.1177/28314425251363983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychedelic Medicine, online erschienen am 30.07.2025. Verfasst von William E Rosa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Sunstone Therapies, National Cancer Institute/NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Psilocybin shows encouraging outcomes for patients with cancer and major depressive disorder (MDD). However, there is insufficient evidence on the use of evidence-based psychotherapeutic interventions to consistently guide and standardize psilocybin preparation, dosing, and integration. Meaning-centered psychotherapy (MCP) is a manualized, brief psychotherapeutic intervention that enhances meaning and purpose among recipients. This article substantiates the rationale for using MCP as a psychotherapeutic intervention to accompany psychedelic-assisted therapy (PAT) with psilocybin for patients with cancer and MDD. Materials and Methods: We sampled seven patients with cancer and MDD who previously received PAT with psilocybin followed by group MCP in a phase 2 open-label trial, as well as six therapists who delivered the interventions. First, electronic open-ended response surveys were distributed to explore participant experiences during the phase 2 trial and elicit recommendations to adapt MCP for psilocybin. Second, the research team developed a 5-session model of MCP and psilocybin therapy (MCP-PSIL) based on survey responses. Finally, four focus groups were conducted (two with patients and two with therapists) to expand on patient experiences during the phase 2 trial and gather feedback on MCP-PSIL.

Results

Seven patients (ages 53–80 years) and six therapists (mental health professional experience ranging 9–44 years) participated in both surveys and focus groups. Focus groups underscored the value of experiences related to psilocybin, the group, and MCP, as distinct elements and in conjunction. Participants shared key recommendations to enhance combined psilocybin and MCP experiences and the 5-session MCP-PSIL model. The importance of the group format was also emphasized while noting that individual MCP may be indicated in certain circumstances.

Conclusion

Findings suggest that MCP is a natural therapeutic partner to guide patients throughout the PAT continuum. As MCP-PSIL is tested in the future, we anticipate MCP will leverage the PAT experience by building therapist capacity to optimize care while reducing avoidable distress for patients and maximizing their meaning-making opportunities.

Schlagwörter

Stichwörter der Autor:innen

cancergroup therapymajor depressive disordermeaning-centered psychotherapypsilocybinpsychedelic-assisted therapy

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • College of Nursing, University of Wisconsin-Milwaukee, Madison, Wisconsin, USA.
  • Sunstone Therapies, Rockville, Maryland, USA.
  • Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: William E Rosa

Förderung

  • NCI NIH HHS
  • Sunstone Therapies
  • National Cancer Institute/NIH

Zitieren

APA

Rosa, W. E., Napolitano, S., McAndrew, N., Jenkins, B., Lichtenthal, W. G., Applebaum, A. J., Breitbart, W., & Agrawal, M. (2026). Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL. Psychedelic Medicine, 4(2), 97-106. https://doi.org/10.1177/28314425251363983

Vancouver

Rosa WE, Napolitano S, McAndrew N, Jenkins B, Lichtenthal WG, Applebaum AJ, et al. Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL. Psychedelic Medicine. 2026;4(2):97-106. doi:10.1177/28314425251363983

BibTeX
@article{Rosa2026,
  author = {Rosa, William E and Napolitano, Stephanie and McAndrew, Natalie and Jenkins, Betsy and Lichtenthal, Wendy G and Applebaum, Allison J and Breitbart, William and Agrawal, Manish},
  title = {Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL},
  journal = {Psychedelic Medicine},
  year = {2026},
  volume = {4},
  number = {2},
  pages = {97--106},
  doi = {10.1177/28314425251363983}
}
Kostenlos starten →